Telesis Bio Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash Flows From Operating Activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization of intangible assets
Amortization of debt discount
Loss on disposal of assets
Impairment of intangible asset
Provision for credit losses
Loss on debt extinguishment
Stock-based compensation
Amortization of operating lease right-of-use assets
Change in fair value of derivative liabilities
Warrants to purchase common stock
Put Option
Participation Rights
Success Fee
Non-cash interest on finance leases
Change in fair value of derivative liabilities
Warrants to purchase common stock
Put Option
Participation Rights
Success Fee
Total change in fair value of derivative liabilities
Loss on disposal of property and equipment
Impairment of property and equipment
Goodwill impairment
Accretion of discount on short-term investments
Changes in operating assets and liabilities:
Accounts receivable
Inventories
Deposits, prepaid expenses and other current assets
Accounts payable, accrued payroll and accrued liabilities
Deferred revenue
Operating lease liabilities
Net cash used in operating activities
Cash Flows From Investing Activities:
Purchase of acquired business, net of cash acquired
Payment of acquisition related costs
Proceeds from maturities of short-term investments
Proceeds from sale of short-term investments
Proceeds from disposal of property and equipment
Purchase of property and equipment
Purchases of short-term investments
Net cash used in investing activities
Cash Flows From Financing Activities:
Borrowings on term loan, net
Repayment of term loan
Borrowings on notes payable, net
Repayment of notes payable
Debt extinguishment costs
Payments on finance leases
Net proceeds from issuance of shares of common stock in initial public offering
Payments of offering costs
Payments of financing costs
Proceeds from the exercise of common stock options
Proceeds from the issuance of common stock related to ESPP
Proceeds from the issuance of preferred stock, net of issuance costs
Proceeds from the issuance of warrants, net of issuance costs
Net cash provided by financing activities
Effect of exchange rate fluctuations on cash held
Net Decrease In Cash, Cash Equivalents, and Restricted Cash
Cash, cash equivalents, and restricted cash at beginning of year
Cash, cash equivalents, and restricted cash at end of year
Supplemental Disclosure Of Cash Flow Information:
Cash paid for interest
Cash paid for taxes
Supplemental Non-Cash Investing and Financing Activities:
Purchases of property and equipment included in accounts payable and accrued expenses
Extinguishment of put option derivative liability in connection with term loan
Issuance of put option derivative liability in connection with term loan
Issuance of preferred stock warrant in connection with term loan
Redeemable convertible preferred stock dividends
Right-of-use-assets obtained in exchange for operating lease liabilities
Equipment obtained in exchange for finance lease liabilities
Right-of-use asset derecognized upon lease modification
Issuance of warrants in connection with notes payable amendment
Extinguishment of put option derivative liability in connection with notes payable
Issuance of put option derivative liability in connection with notes payable
Conversion of shares of convertible preferred stock into common stock
Conversion of warrant into shares of common stock

Comments